The global biosensors for point-of-care diagnostics market is on an upward trajectory, projected to exhibit a substantial Compound Annual Growth Rate (CAGR) of 8.5% between 2023 and 2030, ultimately reaching a market value of approximately US$22.12 billion by the close of 2030.
Market Analysis in Brief
The biosensors for point-of-care diagnostics market encompasses the worldwide demand, manufacturing, and sales of biosensor products tailored for use in point-of-care settings. These biosensors encompass a diverse range of applications, including glucose monitoring for diabetes management, pregnancy tests, infectious disease detection tools, cardiac biomarker analysis, and specialized biosensors designed to facilitate rapid and precise diagnoses. Key drivers for the markets growth include the escalating demand for early disease detection, the increasing prevalence of chronic illnesses, a growing preference for personalized medicine, and the drive to enhance healthcare accessibility and cost-effectiveness.
Key Report Findings
- The global biosensors for point-of-care diagnostics market is expected to grow at a significant rate of 8.5% CAGR from 2023 to 2030.
- The surge in chronic diseases is a major factor driving the demand for biosensors in point-of-care diagnostics.
- Molecular diagnostic biosensors are in high demand within the biosensors for point-of-care diagnostics market.
- Glucose testing, crucial for diabetes management, dominated the biosensors for point-of-care diagnostics market revenue share in 2022.
- Asia Pacific leads the market, while North America is poised for the strongest growth through 2030.
Growing Prevalence of Chronic Diseases: The rising incidence of chronic diseases such as diabetes, hypertension, asthma, and specific cancer types is a significant driver for the biosensors market. Biosensors enable continuous monitoring and real-time data collection for chronic disease management, making them invaluable tools in healthcare.
Increased Healthcare Access and Affordability: Biosensors enhance access to healthcare services, particularly in remote or underserved areas with limited access to centralized medical facilities. They enable on-site testing, reducing the need for multiple visits and waiting times for test results, ultimately improving patient care and access to diagnostics.
Competing Diagnostic Technologies: While biosensors offer numerous advantages, they face competition from established point-of-care diagnostic methods, which may be deeply integrated into existing healthcare systems. Some competing technologies may be more cost-effective or require fewer infrastructure changes, posing a challenge to biosensor adoption.
Under-resourced, Underserved Areas Hold Untapped Opportunity: Biosensors have the potential to expand diagnostic capabilities in resource-constrained regions. They offer a lifeline for underserved populations, providing affordable diagnostic options that are crucial for healthcare access in remote areas.
Overview of Key Segments
Molecular Diagnostic Biosensors Dominant Product Segment: Molecular diagnostic biosensors, which identify and measure biomarkers at the molecular level, are expected to dominate the market. They play a vital role in identifying infectious diseases, such as COVID-19 and hepatitis, and specific cancer biomarkers, enabling early detection and treatment.
Demand for Glucose Testing Continues to Heighten: The glucose testing segment is expected to witness rapid growth, driven by the increasing prevalence of diabetes. Biosensors have revolutionized glucose monitoring, enabling real-time data collection and personalized diabetes management.
Growth Opportunities Across Regions
Asia Pacific Represents the Largest Regional Market: Asia Pacific is expected to lead the biosensors for point-of-care diagnostics market, driven by government initiatives, funding, and favorable regulations. Wearable biosensors and home-based point-of-care diagnostics are gaining traction in the region.
North American Market Set for Fastest Growth: North America is poised for significant growth, with telemedicine integration and the need for rapid point-of-care testing in non-traditional healthcare settings driving demand for biosensors.
Biosensors for Point-of-Care Diagnostics Market: Competitive Landscape
Key players at the forefront of the biosensors for point-of-care diagnostics market include Danaher Corporation, Bio-Rad Laboratories Inc., Zimmer & Peacock AS, Medtronic plc, Koninklijke Philips N.V., Abbott Laboratories, Biosensors International Group, Ltd., DuPont, Johnson & Johnson, LifeScan, Inc., QTL Biodetection LLC, Nova Biomedical, Roche, and Siemens Healthineers AG.
Global Biosensors for Point-of-Care Diagnostics Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2030 (By Product, By Transducer, By Application, By End User, By Geographic Coverage and By Company) https://www.fairfieldmarketresearch.com/report/biosensors-for-point-of-care-diagnostics-market
Our Trending Reports:
Cancer Tissue Diagnostics Market
Food Diagnostics Market
HIV Diagnostics Market
Fairfield Market Research is a UK-based market research provider. Fairfield offers a wide spectrum of services, ranging from customized reports to consulting solutions. With a strong European footprint, Fairfield operates globally and helps businesses navigate through business cycles, with quick responses and multi-pronged approaches. The company values an eye for insightful take on global matters, ably backed by a team of exceptionally experienced researchers. With a strong repository of syndicated market research reports that are continuously published & updated to ensure the ever-changing needs of customers are met with absolute promptness.
Fairfield Market Research
UK +44 (0)20 30025888
USA (Toll-free) +1 (844) 3829746
This press release first seen on Brilad
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Daily Scotland News journalist was involved in the writing and production of this article.